Figure 2.
Randomization to 2500 vs 3500 U/m2 pegaspargase dosage did not affect incidence of pancreatitis, thrombosis, osteonecrosis, and serious hepatotoxicity. (A) Grade ≥2. (B) Grade ≥2. (C) Grade ≥2. (D) Grade ≥3. Green lines are standard/high risk (SHR) patients randomized to receive pegaspargase 2500 U/m2 (n = 117), red lines are SHR patients randomized to receive pegaspargase 3500 U/m2 (n = 116), blue lines are low risk (LR) patients randomized to receive pegaspargase 2500 U/m2 (n = 88), purple lines are LR patients randomized to receive pegaspargase 3500 U/m2 (n = 90). Red P values compare between SHR 2500 U/m2 and SHR 3500 U/m2 patients. Blue P values compare between LR 2500 U/m2 and LR 3500 U/m2 patients. Percentage values show the cumulative incidence of the corresponding toxicity in each risk/dosage group. Only randomized patients were included in these analyses.

Randomization to 2500 vs 3500 U/m2 pegaspargase dosage did not affect incidence of pancreatitis, thrombosis, osteonecrosis, and serious hepatotoxicity. (A) Grade ≥2. (B) Grade ≥2. (C) Grade ≥2. (D) Grade ≥3. Green lines are standard/high risk (SHR) patients randomized to receive pegaspargase 2500 U/m2 (n = 117), red lines are SHR patients randomized to receive pegaspargase 3500 U/m2 (n = 116), blue lines are low risk (LR) patients randomized to receive pegaspargase 2500 U/m2 (n = 88), purple lines are LR patients randomized to receive pegaspargase 3500 U/m2 (n = 90). Red P values compare between SHR 2500 U/m2 and SHR 3500 U/m2 patients. Blue P values compare between LR 2500 U/m2 and LR 3500 U/m2 patients. Percentage values show the cumulative incidence of the corresponding toxicity in each risk/dosage group. Only randomized patients were included in these analyses.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal